Browse Articles

Filter By:

  • Chameleon Biosciences is developing next-generation adeno-associated virus vectors that elicit minimal immune responses, allowing repeat dosing and resulting in superior efficacies. These EVADER vectors have universal application for existing adeno-associated virus vectors, and Chameleon is seeking partners to advance its lead program in severe hemophilia B and to programs that target retinal cells.

    • Chameleon Biosciences
    Advertisement Feature
  • With its lead phase 3 candidate Nefecon in development for the treatment of primary immunoglobulin A nephropathy and a late-stage orphan focused NOX program, Calliditas Therapeutics is pioneering new rare-disease therapies.

    • Calliditas Therapeutics
    Advertisement Feature
  • Funding for early-stage projects and global collaborations are aiming to breathe life into the fragile ecosystem for novel antibiotics.

    • Raveena Bhambra
    News Feature
  • In the past decade, deals involving rare diseases have increased in size and value, supported by the growing number of opportunities based on novel therapeutic platforms.

    • Raveena Bhambra
    • DealForma, LLC
    News Feature
  • Global biotechnology company BioMarin focuses on developing and commercializing innovative therapies through a range of modalities. The company’s diverse pipeline, spanning exploratory to marketed programs, relies heavily on its genetic and genomic expertise, manufacturing capabilities, and long-term partnering models.

    • BioMarin Pharmaceutical Inc.
    Advertisement Feature
  • Seattle’s SEngine is using patient tumor samples to derive cancer organoids for accurate ex vivo drug testing, target identification and drug development.

    • SEngine Precision Medicine
    Advertisement Feature
  • Northern Antibiotics is developing improved versions of polymyxins to help fight against resistant Gram-negative bacteria and has three parallel programs in development.

    • Northern Antibiotics Ltd.
    Advertisement Feature
  • The Swiss pharmaceutical company BioVersys is developing next-generation antimicrobial drugs with unique modes of action targeting a range of multidrug-resistant bacteria.

    • BioVersys AG
    Advertisement Feature
  • Lysando AG’s Artilysin platform technology is producing novel antimicrobial proteins with a unique mode of action and a wide range of applications, from human and veterinary medicine to the food and cosmetics industry. Lysando is licensing the technology to companies all around the world.

    • Lysando AG
    Advertisement Feature
  • Cytophage has developed a versatile bacteriophage-based antibacterial and antiviral technology targeting human and agricultural infectious diseases. With lead programs in avian and swine bacterial infections and in COVID-19, the company is seeking to expand its partnership network.

    • Cytophage Technologies
    Advertisement Feature
  • Amicrobe engineers biologics-as-materials that are applied locally in surgery and trauma to prevent and treat life-threatening infections.

    • Amicrobe, Inc.
    Advertisement Feature
  • Biofilms are a major contributor to the global challenge of antibiotic resistance. BioFilm Control is leading the way in eradicating the biofilm barrier and overcoming antibiotic resistance with compounds that have blockbuster potential.

    • BioFilm Control
    Advertisement Feature
  • Protein engineering company Lytica Therapeutics is pioneering the use of α-helical stapled antimicrobial peptides (StAMPs) to lyse and kill multidrug-resistant bacteria.

    • Lytica Therapeutics, Inc.
    Advertisement Feature
  • Forge Therapeutics has built a proprietary platform called MAGNET (Metalloprotein-targeting Approach to Generating New Experimental Therapeutics) to discover novel-class anti-infectives. With a development candidate to treat infections caused by high-priority Gram-negative pathogens, Forge is advancing its portfolio with partners worldwide.

    • Forge Therapeutics, Inc.
    Advertisement Feature
  • We present a round up of selected biopharma, biotechnology and drug discovery stories published in September 2021 across the Springer Nature portfolio of journals.

    • Raveena Bhambra
    News Feature